September 2022 " Background: Colorectal cancer is the third most common cancer and requires more prognostic biomarkers The expression of several other biomarkers including PPARG, EPCAM, and PD-L1 was investigated by re-analyzing

August 2022 A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer "Adhesion G protein-coupled receptors (adhesion GPCRs), as a member of the G protein-coupled receptors (GPCRs) superfamily, have gradually entered the field of vision of researchers. The structure, function, and involvement of adhesion GPCRs in cancer development have been discussed in a series of papers. Uterine Corpus Endometrial Carcinoma (UCEC) isa malignanttumorofendometrium epithelial, whichis alsooneofthemostcommonfemalereproductivesystemtumors, but there are few pieces of research related to adhesion GPCRs in UCEC." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies." Read more at the source #DrGPCR #GPCR #IndustryNews

and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers approach Published date November 27, 2023 Abstract "Somatostatin receptors are clinically validated GPCR biomarkers We suggest that SST2 and SST3 should be further explored as potential biomarkers and therapeutic tools

Hence, identifying the crucial pathways and biomarkers for the treatment of GBM is of prime importance Our findings suggest that the GNAI3 gene holds potential as a prognostic biomarker for GBM. Chih-Yang Wang Tags G-protein-coupled receptor (GPCR) , genome , glioblastoma , malignancy , molecular biomarker

Additionally, SSTR2 has potential as a new biomarker for poor prognosis in NPC patients." Authors Yue Xu , Zihan Quan , Yuting Zhan , Haihua Wang , Jiadi Luo , Weiyuan Wang , Songqing Fan Tags biomarkers